Listar por autor "Ulazia Garmendia, Ane"
Mostrando ítems 1-5 de 5
-
ADAM12 is a potential therapeutic target regulated by hypomethylation in triple-negative breast cancer
Mendaza Lainez, Saioa
; Ulazia Garmendia, Ane; Monreal Santesteban, Iñaki; Córdoba Iturriagagoitia, Alicia; Ruiz de Azúa, Yerani (MDPI, 2020)
Artículo / Artikulua 
Triple-negative breast cancer (TNBC) is the most aggressive breast cancer subtype and currently lacks any effective targeted therapy. Since epigenetic alterations are a common event in TNBC, DNA methylation profiling can ... -
Búsqueda de nuevos biomarcadores epigenéticos en cáncer de mama triple negativo
(2016) Trabajo Fin de Máster/Master Amaierako Lana
Introducción El estudio de las alteraciones epigenéticas contribuye a la caracterización del subtipo triple negativo (TN) de cáncer de mama (CM). Objetivos Identificar genes diferencialmente metilados entre CM TN y ... -
CDH22 hypermethylation is an independent prognostic biomarker in breast cancer
Martín Sánchez, Esperanza; Mendaza Lainez, Saioa; Ulazia Garmendia, Ane; Monreal Santesteban, Iñaki; Córdoba Iturriagagoitia, Alicia; Vicente García, Francisco; Blanco Luquin, Idoia; Cruz, Susana de la; Aramendia, Ana; Guerrero Setas, David (BioMed Central, 2017)
Artículo / Artikulua
Background: Cadherin-like protein 22 (CDH22) is a transmembrane glycoprotein involved in cell-cell adhesion and metastasis. Its role in cancer is controversial because it has been described as being upregulated in ... -
CHL1 hypermethylation as a potential biomarker of poor prognosis in breast cancer
Martín Sánchez, Esperanza; Mendaza Lainez, Saioa; Ulazia Garmendia, Ane; Monreal Santesteban, Iñaki; Blanco Luquin, Idoia; Córdoba Iturriagagoitia, Alicia; Vicente García, Francisco; Pérez Janices, Noemi; Escors Murugarren, David; Megías, Diego (Impact Journals, 2017)
Artículo / Artikulua
The CHL1 gene encodes a cell-adhesion molecule proposed as being a putative tumour-suppressor gene in breast cancer (BC). However, neither the underlying molecular mechanisms nor the clinical value of CHL1 downregulation ... -
A DNA methylation-based gene signature can predict triple-negative breast cancer diagnosis
Mendaza Lainez, Saioa; Guerrero Setas, David; Monreal Santesteban, Iñaki; Ulazia Garmendia, Ane; Córdoba Iturriagagoitia, Alicia; Cruz, Susana de la; Martín Sánchez, Esperanza (MDPI, 2021)
Artículo / Artikulua
Triple-negative breast cancer (TNBC) is the most aggressive breast cancer (BC) subtype and lacks targeted treatment. It is diagnosed by the absence of immunohistochemical expression of several biomarkers, but this method ...
